Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$620.0 million","upfrontCash":"$90.0 million","newsHeadline":"Capsida Biotherapeutics Debuts with $140 Million of Capital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Capsida","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Capsida","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Capsida","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Capsida","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"$55.0 million","newsHeadline":"Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$665.0 million","upfrontCash":"$70.0 million","newsHeadline":"AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery"},{"orgOrder":0,"company":"Capsida","sponsor":"Kate Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx's Next-Generation Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Capsida

    Menu

    Capsida

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Capsida

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx's Next-Generation Gene Therapies

              Details:

              Under the terms of the agreement, Capsida will provide GMP manufacturing of KateTx's gene therapies as the medicines advance through preclinical and clinical development for muscle and heart disease programs.

              Lead Product(s): Undisclosed

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Kate Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Capsida

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need

              Details:

              Under the terms of the collaboration, AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs.

              Lead Product(s): Undisclosed

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: AbbVie Inc

              Deal Size: $665.0 million Upfront Cash: $70.0 million

              Deal Type: Collaboration February 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Capsida

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases

              Details:

              Delivering AAV gene therapy systemically to target the CNS, while limiting exposure to non-target organs (such as the liver), has been a significant challenge in the gene therapy field.

              Lead Product(s): AAV-based Gene Therapy

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Prevail Therapeutics

              Deal Size: $740.0 million Upfront Cash: $55.0 million

              Deal Type: Collaboration January 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Capsida

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual ...

              Details:

              Adeno-Associated Virus Engineering Platform, Platform utilizes combinatorial engineering and automation to screen in high-throughput, generating capsids greatly improved over AAV9 in CNS efficiency and specificity.

              Lead Product(s): AAV9-based Gene Therapy

              Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Capsida

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & C...

              Details:

              CAP-001, a novel engineered capsid packaging a human iduronate-2-sulfatase (IDS) transgene, achieved greater than 25- and 2-fold higher biodistribution than AAV9 delivered IV or intrathecally via intracisternal magna.

              Lead Product(s): CAP-001

              Therapeutic Area: Genetic Disease Product Name: CAP-001

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Capsida

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies

              Details:

              Under the agreement, CRISPR Therapeutics will lead R&D of the Friedreich’s ataxia program and perform gene-editing activities for both programs, and Capsida will lead research and development of the ALS program and conduct AAV vectors engineering for both programs.

              Lead Product(s): AAV-based Gene Therapy

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Recipient: CRISPR Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Capsida

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Capsida Biotherapeutics Debuts with $140 Million of Capital

              Details:

              Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie. The collaboration is aimed at developing best-in-class, targeted gene therapies for three programs in serious neurodegenerative diseases.

              Lead Product(s): AAV-based gene therapy

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: AbbVie Inc

              Deal Size: $620.0 million Upfront Cash: $90.0 million

              Deal Type: Collaboration April 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY